Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J4U0 | ISIN: US6092071058 | Ticker-Symbol: KTF
Tradegate
01.11.24
21:51 Uhr
63,40 Euro
+0,19
+0,30 %
1-Jahres-Chart
MONDELEZ INTERNATIONAL INC Chart 1 Jahr
5-Tage-Chart
MONDELEZ INTERNATIONAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
62,3763,6513:03
63,0263,4001.11.
GlobeNewswire (Europe)
838 Leser
Artikel bewerten:
(2)

Mondelez International, Inc.: Mondelez International's Near-term 2030 Targets and 2050 Net-Zero Targets Validated by Science Based Targets Initiative

  • Approval reinforces Mondelez International's commitment to its mission to create a more sustainable snacking company

CHICAGO, April 09, 2024 (GLOBE NEWSWIRE) -- Mondelez International, Inc. (Nasdaq: MDLZ) joins the companies leading the journey to net-zero as it announced today that the Science Based Targets initiative (SBTi) has validated its near-term 2030 greenhouse gas reduction targets and its net-zero target by 2050.

"We are proud to have SBTi approve our 2030 targets and our 2050 net-zero target as it further strengthens our commitment to more sustainable snacking," said Christine Montenegro McGrath, Chief Impact and Sustainability Officer. "We are on our way toward our net-zero ambition and helping make sustainability a reality."

"Our ESG approach is designed to enable us to deliver lasting change at scale by prioritizing where we can have the greatest impact, focusing on innovative and measurable solutions, and collaborating to drive sector-wide transformation," said Chairman and CEO Dirk van de Put. "We've taken an end-to-end approach in our aim to reach our net-zero emissions goal by focusing efforts across key areas and delivering against existing goals."

Mondelez International made significant progress against these goals in 2023, including:

  • Reducing end-to-end CO2e emissions by ~(3.7)%, on track for ~35% reduction end-to-end by 2030 (from a 2018 base year)1
  • In 2023, ~48% of the electricity used in our manufacturing sites was renewable, compared to ~40% in 20222
  • In 2023, ~96% of our packaging was designed to be recyclable3
  • We are on track for cocoa, palm, soy and paper materials to be deforestation free by the end of this year in the EU and by the end of 2025 globally

These efforts support the company's Vision 2030 long-term growth strategy, which includes Sustainability as a critical pillar.

To learn more about our science-based targets, please visit the ESG at MDLZ | Mondelez International, Inc. (mondelezinternational.com)

About Mondelez International
Mondelez International, Inc. (Nasdaq: MDLZ) empowers people to snack right in over 150 countries around the world. With 2023 net revenues of approximately $36 billion, MDLZ is leading the future of snacking with iconic global and local brands such as Oreo, Ritz, LU, Clif Bar and Tate's Bake Shop biscuits and baked snacks, as well as Cadbury Dairy Milk, Milka and Toblerone chocolate. Mondelez International is a proud member of the Standard and Poor's 500, Nasdaq 100 and Dow Jones Sustainability Index. Visit www.mondelezinternational.com or follow the company on Twitter at www.twitter.com/MDLZ.

Contacts:Maggie McKerr
1-847-943-5678
news@mdlz.com

1 Reported information following Science Based Targets initiative (SBTi) guidelines for near-term 2030 target excludes Capital Goods, Upstream Transportation and Distribution of Raw Materials, Business Travel Accommodation, Employee Commuting, Downstream Transportation at Customer, Consumer Use of Sold Products and End of Life Treatment. The long-term 2050 target excludes these same categories, except for Capital Goods, Upstream Transportation and Distribution of Raw Materials and Employee Commuting. The footprint includes all acquisitions and divestitures to date except for Chipita and Ricolino (subject to future data integration). In the reporting year 2023, our annual GHG emissions were accounted following the GHG Protocol Corporate Standards and using the operational control approach. We have recalculated our base year 2018 and most recent years 2022 and 2023 inventory following the GHG Protocol Corporate Standards. For more details, please see the Carbon Accounting Manual. Reported information based on latest estimate; independent, third-party verification in-progress. Any updates, if needed, to be included in the ESG Datasheet. Once completed, SGS verification can be found in our ESG Reporting & Disclosure Reporting Archive.

2 Reported information excludes developed-market gum brands, which were divested as of October 1, 2023 (which differs from previous years). We have recalculated our baseline year (where applicable) and our most recent years 2021, 2022 and 2023 for year-over-year comparison. Reported information based on latest estimate; independent, third-party verification in-progress. Any updates, if needed, to be included in the ESG Datasheet. Once completed, SGS verification can be found in our ESG Reporting & Disclosure Reporting Archive.

3 Reported information covers the period from November 1, 2022 through October 31, 2023.


A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d3f9efe2-8fcc-469b-b829-ef3550e86770


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.